Dersimelagon not checked

Tanabe Pharma America, Inc. · MT-7117

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
1 active
12 in total · 2 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
EPP, XLP
Main trialPhase 3
“To evaluate the long-term safety and tolerability of oral dersimelagon.”In the company’s words, NCT05005975 on ClinicalTrials.gov
Other names
MT-7117

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials12

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting Dec 2027 Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
Phase 3Completed 14 Dec 2021 Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria
Phase 3Completed 14 Apr 2026 INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP
Phase 2Completed 28 Sep 2019 Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria
Phase 2Completed 17 Jan 2024 Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis
Phase 1Completed 11 May 2018 Mass Balance Study With MT-7117
Phase 1Completed 22 Dec 2018 Relative Bioavailability and Drug-drug Interaction Study With MT-7117 and a Proton Pump Inhibitor
Phase 1Completed 16 Feb 2021 Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function
Phase 1Completed 4 Dec 2021 PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function
Phase 1Completed 4 Feb 2022 Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy Subjects
Phase 1Completed 23 Feb 2022 Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects
Phase 1Completed 21 Jul 2025 The Purpose of This Study is to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects.
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Dersimelagon

Following is part of Solo: you see every change to Dersimelagon the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in